Market
Unusual case of a medical IT platform company acquiring control of a vaccine developer; board overhaul planned after payment is completed, while shares hit the daily upper limit after the disclosure

Cellid, a KOSDAQ-listed biotechnology company, has decided to issue 10 billion won worth of new shares through a third-party allotment, making medical IT platform company Huniverse Global its largest shareholder. Cellid, which has continued research on cancer immunotherapy vaccines and COVID-19 vaccines, is set to gain a new owner after experiencing financial difficulties amid delays in generating cash from its core business. The market is watching the transaction as an unusual convergence of a traditional biotechnology company and a digital health care company.
Control to Transfer Through Acquisition of All New Shares
Cellid held a board meeting on the 21st and resolved to issue 4,796,163 common shares, the company disclosed on the 22nd. The issue price is 2,085 won per share, bringing the total amount raised to 9,999,998,550 won. The issue price was calculated at a 10% discount to the reference share price of 2,316 won, calculated using the day before the board resolution as the base date.
The offering will be conducted through a third-party allotment, with Huniverse Global acquiring all of the new shares. Cellid said, “Upon completion of the payment, the largest shareholder is expected to change to Huniverse Global, which intends to participate in management.” This is not simply an equity investment but an effective acquisition of management control. Once payment for the offering is completed, the board will be overhauled, with four directors, including a chief executive officer designated by Huniverse Global, and one auditor newly appointed.
The payment date for the new shares is Nov. 9, and the scheduled listing date is Nov. 30. All of the issued shares will be subject to a one-year lockup, and the company was exempted from filing a securities registration statement because the shares were issued privately and are subject to the lockup. As of the contract date, Cellid’s market capitalization was approximately 82.8 billion won, and the 10 billion won investment represents approximately 12.1% of its market capitalization. On the 22nd, when the change in management control was disclosed, Cellid’s share price surged 29.95% from the previous day to reach the daily upper limit of 2,885 won.
Why a Company With 800 Million Won in Capital Is Investing 10 Billion Won
Huniverse Global is led by CEO Lee Sang-heon and is a medical IT platform company launched in 2019 by the Precision Medicine Project Group under Korea University Medical Center. Its largest shareholder is Korea University Medical Technology Holdings, which owns a 37% stake. The company has built the world’s first cloud-based hospital information system at the level of a tertiary general hospital through a national project of South Korea’s Ministry of Health and Welfare.
Its financial scale, however, remains at the startup level. As of the 2025 fiscal year-end, total assets were 8.924 billion won and total equity was 814 million won, while liabilities amounted to 8.11 billion won. With annual revenue of 3.41 billion won and a net loss of 2.98 billion won, the company appears to have expanded its business with support from its parent university holding company. Cellid said, “Huniverse Global was selected as the allottee after comprehensively considering the investor’s ability to make the payment, the timing at which payment could be made and its investment intentions.”
Market experts say investors’ sentiment improved significantly on expectations that Cellid’s financial uncertainty would be resolved through the recruitment of a new largest shareholder, although reliance on rights offerings had increased fatigue among existing shareholders.
Market Watches Potential Combination of IT Data and Drug Development
The entire 10 billion won raised will be used for operating expenses. Cellid plans to use 4.999 billion won in 2027 and 5 billion won from 2028 onward for operating expenses needed to run the company. The funds are expected to serve as operating capital for key pipelines, including clinical trials of COVID-19 variant vaccines, and to accelerate commercialization.
The market is watching how Huniverse Global’s medical big data and artificial intelligence technologies could be used to identify Cellid’s new biotechnology pipelines. The acquisition of a vaccine developer by an IT company that operates a cloud-based hospital information system and handles medical big data is being viewed as an example of the precision medicine trend in South Korea’s health care industry, in which IT data and drug development are being combined.
Meanwhile, additional new investment, including the issuance of convertible bonds, is also expected to follow the acquisition of management control. How Cellid’s business portfolio will be reorganized under the new largest shareholder is expected to become clearer after payment is completed in November.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
Medtronic to Acquire Contego Medical for $380 Million, Strengthening Carotid Treatment Portfolio

AstraZeneca wins Soliris antitrust lawsuit, with court finding no patent abuse

Alphabet Subsidiary Isomorphic Raises $5 Billion for AI Drug Development

Google Subsidiary Isomorphic Raises Another $5 Billion in Funding in Six Months

Lilly invests $7.9 billion in cancer-targeting technology company in fourth deal in 6 weeks

Samsung Biologics Completes 2.665 Trillion Won Rights Offering; New Shares to List Nov. 30